Ben Shepherd

Ben Shepherd has a diverse work experience spanning over two decades. Ben is currently working as the Co-founder and CEO of Trestle Biotherapeutics since January 2020. Prior to that, Ben held various roles at Organovo Holdings, Inc. from 2018 to 2019, including Vice President of Research and Preclinical Development and Senior Director of Therapeutics. Ben also worked at Organovo, Inc. from 2012 to 2018, where they served as Director of Therapeutics, Associate Director of R&D and Business Development & Preclinical Study Director, and Program Leader of Tissue Applications. Earlier in their career, Ben worked as an Associate Research Scientist and Postdoctoral Fellow at Yale University School of Medicine and as a Graduate Student at the University of Arizona.

Ben Shepherd began their education at the University of Washington in 1995, where they pursued a Bachelor of Science degree in Zoology. Ben spent four years at the institution, completing their undergraduate education in 1999. Following this, Ben proceeded to the University of Arizona, where they began their doctoral studies in Physiological Sciences. Ben spent four years at the university, eventually earning their PhD degree in 2003.